Tonix Pharmaceuticals/$TNXP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Ticker
$TNXP
Sector
Primary listing
Employees
142
Headquarters
Website
TNXP Metrics
BasicAdvanced
$190M
-
-$14.57
1.86
-
Price and volume
Market cap
$190M
Beta
1.86
52-week high
$69.97
52-week low
$13.07
Average daily volume
328K
Financial strength
Current ratio
7.422
Quick ratio
6.955
Long term debt to equity
0.483
Total debt to equity
0.534
Interest coverage (TTM)
-1,412.39%
Profitability
EBITDA (TTM)
-123.778
Gross margin (TTM)
49.34%
Net profit margin (TTM)
-946.22%
Operating margin (TTM)
-959.05%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-35.71%
Return on equity (TTM)
-64.48%
Valuation
Price to revenue (TTM)
9.215
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-1.17
Free cash flow yield (TTM)
-85.46%
Free cash flow per share (TTM)
-12.127
Growth
Revenue change (TTM)
29.85%
Earnings per share change (TTM)
-91.75%
What the Analysts think about TNXP
Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.
TNXP Financial Performance
Revenues and expenses
TNXP Earnings Performance
Company profitability
TNXP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tonix Pharmaceuticals stock?
Tonix Pharmaceuticals (TNXP) has a market cap of $190M as of March 19, 2026.
What is the P/E ratio for Tonix Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tonix Pharmaceuticals (TNXP) stock is 0 as of March 19, 2026.
Does Tonix Pharmaceuticals stock pay dividends?
No, Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders as of March 19, 2026.
When is the next Tonix Pharmaceuticals dividend payment date?
Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders.
What is the beta indicator for Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.